These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 22297638)
61. Utility of PHH3 in Evaluation of Mitotic Index in Breast Carcinoma and Impact on Tumor Grade. Mirzaiian E; Tabatabaei Ghods ZS; Tavangar SM; Emami B; Oraie M; Safyari R; Saffar H Asian Pac J Cancer Prev; 2020 Jan; 21(1):63-66. PubMed ID: 31983165 [TBL] [Abstract][Full Text] [Related]
62. Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma. Shimizu A; Kaira K; Kato M; Yasuda M; Takahashi A; Tominaga H; Oriuchi N; Nagamori S; Kanai Y; Oyama T; Asao T; Ishikawa O Melanoma Res; 2015 Oct; 25(5):399-405. PubMed ID: 26237765 [TBL] [Abstract][Full Text] [Related]
63. The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study. Chow KL; Tse KY; Cheung CL; Wong KW; Cheung AN; Wong RW; Chan AN; Yuen NW; Ngan HY; Ip PP Histopathology; 2017 Apr; 70(5):746-755. PubMed ID: 27864989 [TBL] [Abstract][Full Text] [Related]
64. Fractal dimension of chromatin is an independent prognostic factor for survival in melanoma. Bedin V; Adam RL; de Sá BC; Landman G; Metze K BMC Cancer; 2010 Jun; 10():260. PubMed ID: 20525386 [TBL] [Abstract][Full Text] [Related]
65. Frequent mitotic activity in banal melanocytic nevi uncovered by immunohistochemical analysis. Glatz K; Hartmann C; Antic M; Kutzner H Am J Dermatopathol; 2010 Oct; 32(7):643-9. PubMed ID: 20661119 [TBL] [Abstract][Full Text] [Related]
66. Gastrointestinal Stromal Tumors Risk Stratification Utilizing Phospho-Histone H3 Evaluated by Manual Counting and Computer-Assisted Image Analysis. Jin C; Huang Y; Nasim M; Yang Y; Lee L Int J Surg Pathol; 2019 Oct; 27(7):706-712. PubMed ID: 31146625 [No Abstract] [Full Text] [Related]
67. Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score. Zbytek B; Cohen C; Wang J; Page A; Williams DJ; Adams AL Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):48-53. PubMed ID: 22495373 [TBL] [Abstract][Full Text] [Related]
68. The Utility of Phosphohistone H3 in Breast Cancer Grading. Cui X; Harada S; Shen D; Siegal GP; Wei S Appl Immunohistochem Mol Morphol; 2015; 23(10):689-95. PubMed ID: 25611243 [TBL] [Abstract][Full Text] [Related]
69. The Utility of Phosphohistone H3 in Inter-Observer Variability of Mitotic Count in Meningioma, is There Any Benefit? Saffar H; Okhovat H; Arbabsoleymani S; Tavangar SM; Khoshnevisan A; Hajinasrollah G; Hamidi Afra Z; Saffar H Asian Pac J Cancer Prev; 2021 Jul; 22(7):2049-2052. PubMed ID: 34319026 [TBL] [Abstract][Full Text] [Related]
70. Phosphohistone-H3 Proliferation Index Is Superior to Mitotic Index and MIB-1 Expression as a Predictor of Recurrence in Human Meningiomas. Winther TL; Arnli MB; Salvesen Ø; Torp SH Am J Clin Pathol; 2016 Oct; 146(4):510-20. PubMed ID: 27686177 [TBL] [Abstract][Full Text] [Related]
71. Independent prognostic importance of vascular invasion in nodular melanomas. Straume O; Akslen LA Cancer; 1996 Sep; 78(6):1211-9. PubMed ID: 8826942 [TBL] [Abstract][Full Text] [Related]
72. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Barnhill RL; Fine JA; Roush GC; Berwick M Cancer; 1996 Aug; 78(3):427-32. PubMed ID: 8697387 [TBL] [Abstract][Full Text] [Related]
73. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Azzola MF; Shaw HM; Thompson JF; Soong SJ; Scolyer RA; Watson GF; Colman MH; Zhang Y Cancer; 2003 Mar; 97(6):1488-98. PubMed ID: 12627514 [TBL] [Abstract][Full Text] [Related]
74. Global and mitosis-specific interobserver variation in mitotic count scoring and implications for malignant melanoma staging. Saldanha G; Ali R; Bakshi A; Basiouni A; Bishop R; Colloby P; Craig P; Da Forno P; Edward S; Espinosa de Los Monteros O; Evans A; Jamieson L; Rytina E; Bamford M Histopathology; 2020 May; 76(6):803-813. PubMed ID: 31879972 [TBL] [Abstract][Full Text] [Related]
75. Anti-phosphohistone H3 as an independent prognostic factor in human esophageal squamous cell carcinoma. Nakashima S; Shiozaki A; Ichikawa D; Komatsu S; Konishi H; Iitaka D; Kubota T; Fujiwara H; Okamoto K; Kishimoto M; Otsuji E Anticancer Res; 2013 Feb; 33(2):461-7. PubMed ID: 23393337 [TBL] [Abstract][Full Text] [Related]
76. Mitotic rate in cutaneous melanomas ≤1 mm in thickness: a prospective study. Litzner BR; Etufugh CN; Stepenaskie S; Hynan LS; Cockerell CJ Am J Dermatopathol; 2012 Dec; 34(8):827-32. PubMed ID: 22878366 [TBL] [Abstract][Full Text] [Related]
77. Tumor Budding in Colorectal Carcinoma Showing a Paradoxical Mitotic Index (Via PHH3) With Possible Association to the Tumor Stromal Microenvironment. Hacking S; Sajjan S; Angert M; Ebare K; Jin C; Chavarria H; Kataria N; Zhang L; Cho M; Thomas R; Lee L; Nasim M Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):627-634. PubMed ID: 31567276 [TBL] [Abstract][Full Text] [Related]
78. Mitotic rate and subcutaneous involvement are prognostic factors for survival after recurrence in patients with only locoregional skin metastasis as the first site of recurrence from cutaneous melanoma. Messeguer F; Agustí-Mejías A; Traves V; Requena C; Alegre V; Guillén C; Oliver V; Nagore E J Eur Acad Dermatol Venereol; 2013 Apr; 27(4):436-41. PubMed ID: 22303982 [TBL] [Abstract][Full Text] [Related]
79. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer. van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844 [TBL] [Abstract][Full Text] [Related]
80. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. Gimotty PA; Van Belle P; Elder DE; Murry T; Montone KT; Xu X; Hotz S; Raines S; Ming ME; Wahl P; Guerry D J Clin Oncol; 2005 Nov; 23(31):8048-56. PubMed ID: 16258103 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]